Partnership Topics and PR's:
I was bored at work so, I went through every PR released by PPHM Since October 17, 2012 and highlighted all of the relevant sentences related to "Partner" and "Partnership". It is only mentioned in the SUB-HEADER only TWICE. Once on December 5, 2012 and the other time on June 27, 2013. The rest of the time it is mentioned in the body of the PR's.
From what I can tell, PPHM does have potential partners (plural) who are interested because in February, they were "...continuing to update potential partners..." Prior to that PR, they were "seeking". If there was no one interested, there would be no need to update anyone.
October 17, 2012:
Title: Peregrine Pharmaceuticals Provides Update on Corporate Activities
Body of PR:
"The company plans to seek partners both in the U.S. and internationally to support the development of Cotara for this deadly form of brain cancer. "
October 31, 2012
Title: New Data Support Ability of PS-Targeting Antibodies to Specifically Target Tumors and Stimulate Cancer-Fighting Immune Responses
No mention of Partner
November 14, 2012
Title: Peregrine Pharmaceuticals Announces Receipt of Notice From NASDAQ
No mention of Partner
December 3, 2012
Title: Peregrine to Report Second Quarter Fiscal Year 2013 Financial Results After Market Close on December 10, 2012
No mention of Partner
December 5, 2012
Title: Peregrine Pharmaceuticals Announces Significant Progress in Advancing Its Cotara Program Into a Pivotal Phase III Trial
Subheader of PR: "...While Advancing Partnering Discussions"...
Body of PR:
"Having achieved this goal, we are now beginning to plan for this global registration study while continuing partnering discussions."
"Having established a clear clinical path forward for this novel and targeted delivered drug candidate, we can now escalate our business development activities to secure a partnership, recognizing the great interest by companies in drug candidates within the orphan and rare disease space,"
December 10, 2012
Title: Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2013 Financial Results and Recent Developments
Body of PR:
"The company plans to seek partners both in the U.S. and internationally to support the development of Cotara for this deadly form of brain cancer."
December 11, 2012
Title: Peregrine Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement
No mention of Partner
January 7, 2013
Title: Peregrine Pharmaceuticals Provides Update on the Internal Review of Its Phase II Second-Line Non-Small Cell Lung Cancer Trial
Body of PR:
"With the results of this review in hand, we are now in the process of updating potential partners and moving the program forward,"
February 13, 2013
Title: Peregrine Pharmaceuticals Announces Results From Phase II Clinical Trial of Bavituximab in Stage IV Pancreatic Cancer
No mention of Partner
February 19, 2013
Title: Peregrine Pharmaceuticals Updates Top-Line Data From Phase II Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer
Body of PR:
"we are continuing to update potential partners on these trial results and our future plans for advancing the program. Partnering interest remains high and the updates from this trial should help advance these discussions. "
February 26, 2013
Title: Avid Bioservices to Highlight Recent Successes in Reducing Manufacturing Costs and Novel Ways of Controlling Critical Process Parameters That Lead to Consistent Product Quality at IBC'S Biopharmaceutical Development and Production Conference
No mention of Partner
February 26, 2013
Title: Peregrine Announces Participation at Upcoming Investor Conferences
NNo mention of Partner
March 5, 2013
Title: Peregrine to Report Third Quarter Fiscal Year 2013 Financial Results After Market Close on March 12, 2013
No mention of Partnerr
March 12, 2013
Title: Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2013 Financial Results and Recent Developments
Body of PR:
We are continuing to update potential partners on the new data as well as our plans for advancing the program."
April 1, 2013
Title: Peregrine Announces Three Abstracts Accepted for Presentation at AACR 2013 Annual Meeting
No mention of Partner
April 10, 2013
Title: Data Presented at AACR Annual Meeting Support Targeted Immune Reactivation Mechanism and Potential of Peregrine's Bavituximab in Solid Tumor Therapy
No mention of Partner
April 29, 2013
Title: Peregrine Announces Completion of Patient Enrollment in Breast Cancer Clinical Trial for Bavituximab
No mention of Partner
May 16, 2013
Title: Peregrine Pharmaceuticals' Immunotherapy Bavituximab to Be Highlighted in Three Clinical Data Presentations at 2013 ASCO Annual Meeting
No mention of Partner
May 20, 2013
Title: Peregrine Pharmaceuticals Reaches Agreement With FDA on a Phase III Trial Design for Bavituximab in Second-Line Non-Small Cell Lung Cancer
Body of PR:
"We will now focus on starting the Phase III trial while continuing ongoing partnering discussions.
June 3, 2013
Title: Data Presented at ASCO Shows Promising 11.7 Month Median Overall Survival in Second-Line NSCLC Patients Treated With Peregrine Pharmaceuticals' Novel Immunotherapy Bavituximab
Body of PR:
"We look forward to advancing our ongoing partnering discussions while continuing our plans to initiate this important Phase III clinical trial by year-end."
June 3, 2013
Title: Encouraging Results in Breast and Pancreatic Cancers for Patients Treated With Peregrine's Novel Immunotherapy Bavituximab Presented at ASCO
No mention of Partner
June 24, 2013
Title: Peregrine Pharmaceuticals to Join Russell 3000 and Russell Global Indexes
No mention of Partner
June 27, 2013
Title: Peregrine Pharmaceuticals Provides Update on Bavituximab Clinical Program
Subheader of PR: Company Strengthens Cash Position as It Prepares to Initiate Phase III Trial in Second-Line NSCLC by Year-End While Partnering Discussions Continue;
Body of PR:
"The recent agreement with the FDA on the Phase III trial design, along with the successful fundraising efforts have positioned us well for advancing the program into Phase III development, and have strengthened our position to develop the compound including ongoing partnering discussions,"
"By strengthening our cash position we have given ourselves the needed flexibility to prepare for the upcoming Phase III trial, explore the potential of bavituximab's immune mechanism and to strengthen our position in partnering discussions,"
July 2, 2013
Title: Peregrine to Report Fourth Quarter and Year-End Fiscal Year 2013 Financial Results After Market Close on July 11, 2013
No mention of Partner
